190A — Chordia Therapeutics Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Chordia Therapeutics, fiscal year end - August 31st, JPY millions except per share, conversion factor applied.
2022 August 31st | 2023 August 31st | 2024 August 31st | 2025 August 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Yuho | Tanshin |
| Standards: | JAS | JAS | JAS | — |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 2,500 | 0 | — |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 1,844 | 2,288 | 1,801 | 1,804 |
| Operating Profit | -1,844 | 212 | -1,801 | -1,804 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -1,777 | 226 | -1,825 | -1,783 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -1,779 | 223 | -1,827 | -1,786 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -1,779 | 223 | -1,827 | -1,786 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -1,779 | 223 | -1,827 | -1,786 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -27.1 | 3.41 | -31.1 | -25.9 |
| Dividends per Share |